Compare EUDA & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EUDA | TLPH |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 64.7M |
| IPO Year | N/A | 2011 |
| Metric | EUDA | TLPH |
|---|---|---|
| Price | $2.40 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 645.4K | 422.0K |
| Earning Date | 12-19-2023 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $5,160,280.00 | $28,000.00 |
| Revenue This Year | $137.25 | N/A |
| Revenue Next Year | $361.43 | $14,267.20 |
| P/E Ratio | $338.58 | ★ N/A |
| Revenue Growth | ★ 83.73 | N/A |
| 52 Week Low | $1.03 | $0.38 |
| 52 Week High | $4.70 | $1.57 |
| Indicator | EUDA | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 39.26 |
| Support Level | $1.21 | $1.02 |
| Resistance Level | $2.96 | $1.22 |
| Average True Range (ATR) | 0.56 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 61.43 | 16.67 |
EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security property management services provided to all tenants and property owners.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.